New weight loss drug shows promise in early trial
NCT ID NCT07121153
First seen Feb 25, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This study tested a new medicine called NNC0487-0111 for weight control in 36 Chinese adults with overweight or obesity. Participants received either the drug or a placebo injection. The main goal was to check safety and how the drug moves through the body. The trial lasted up to 53 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Jinan Central Hospital
Jinan, Shandong, 250000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NNC0487-0111
What this could lead to
If this drug is safe and works, it could offer a new option for weight management in people with overweight or obesity.
What could go wrong
This is an early Phase 1 trial with only 36 participants, so it's too soon to know if the drug is effective or safe long-term. Many drugs fail in early testing.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.